PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. |
Incorporation of Documents by Reference |
The following documents previously filed with the Commission are incorporated herein by reference:
(a) The Companys Annual Report on Form 10-K for the year ended December 31, 2023, filed with
the Commission on February 28, 2024.
(b) The Companys Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, filed
with the Commission on May 8, 2024.
(c) The Companys Annual Meeting Proxy Statement, filed with the Commission on April
10, 2024.
(d) The Companys Current Reports on Form 8-K filed on January
24, 2023 (as amended on April
10, 2023), January
5, 2024, January
9, 2024, February
21, 2024, February
29, 2024, March
13, 2024, May
8, 2024, May
21, 2024, and May 30, 2024.
(e) The description of the Common Shares filed with the Commission on Form 8-A12B on September
29, 2006, as amended on October 18, 2006.
All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities
Exchange Act of 1934, as amended (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of
this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to
be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall
be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or
supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
You may obtain a copy of any of these documents at no cost by requesting them from us or by writing or calling: Catalyst Pharmaceuticals,
Inc., 355 Alhambra Circle, Suite 801, Coral Gables, Florida, 33134, Attn: Investor Relations, or by calling (305) 420-3200. Copies of each of these filings are also available for no cost on our
website, www.catalystpharma.com, or on the SECs web site, www.sec.gov.
Item 4. |
Description of Securities |
Please refer to the description of our capital stock contained under the description of the Companys securities registered under
Section 12 of the Exchange Act contained in Exhibit 4.5 to the Companys Annual Report on Form 10-K
for the year ended December 31, 2021, filed with the SEC on March 16, 2022, together with any
amendment thereto filed with the SEC for the purpose of updating such description.
Item 5. |
Interests of Named Experts and Counsel |
Not applicable.
3